{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061466","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.547622+00:00","generated_at":"2026-05-23T01:35:59.268097+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lineage Cell Therapeutics completes cGMP production run for two product candidates","bullets":["Successfully produced two product candidates using a two-tiered cGMP cell banking system from a single pluripotent cell line.","System uses a genetically-stable master cell bank to generate a working cell bank for final product.","Company states the process could enable millions of doses of consistent, cost-effective allogeneic cell therapy.","Risk factor added: no assurance of consistent cGMP manufacturing at commercial scale or cost-effectiveness."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061466","json":"https://secwatch.observer/filing/0000950170-25-061466.json","markdown":"https://secwatch.observer/filing/0000950170-25-061466.md","text":"https://secwatch.observer/filing/0000950170-25-061466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017025061466/0000950170-25-061466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017025061466/lctx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:35:59.268097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}